Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients

References

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA (Chicago, Ill.) 285:2486–2497.
   Google Scholar
• American Diabetes Association (2004). Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1:S5–S10.
   PubMedGoogle Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. (1993). Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41.
   PubMed Web of Science ®Google Scholar
• Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. (2011). ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol 57:2037–2114.
   PubMedGoogle Scholar
• Ben-Tal Cohen E, Hohensinner PJ, Kaun C, Maurer G, Huber K, Wojta J. (2007). Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol 73:77–83.
   PubMed Web of Science ®Google Scholar
• Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. (2006). Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 26:2117–2124.
   PubMed Web of Science ®Google Scholar
• Browner WS, Lui LY, Cummings SR. (2001). Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86:631–637.
   PubMed Web of Science ®Google Scholar
• Chang KC, Lee HC, Tseng MC, Huang YC. (2010). Three-year survival after first-ever ischemic stroke is predicted by initial stroke severity: A hospital-based study. Clin Neurol Neurosurg 112:296–301.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Norrving B, Terént A, Stegmayr B. (2008). Functional outcome 3 months after stroke predicts long-term survival. Cerebrovasc Dis 25:423–429.
   PubMed Web of Science ®Google Scholar
• Golledge J, McCann M, Mangan S, Lam A, Karan M. (2004). Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35:1636–1641.
   PubMed Web of Science ®Google Scholar
• Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, Arikan E, Tugrul A. (2007). Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 120:511–516.
   PubMed Web of Science ®Google Scholar
• Harari OA, Liao JK. (2010). NF-?B and innate immunity in ischemic stroke. Ann N Y Acad Sci 1207:32–40.
   PubMed Web of Science ®Google Scholar
• Helske S, Kovanen PT, Lindstedt KA, Salmela K, Lommi J, Turto H, Werkkala K, Kupari M. (2007). Increased circulating concentrations and augmented myocardial extraction of osteoprotegerin in heart failure due to left ventricular pressure overload. Eur J Heart Fail 9:357–363.
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O’Brien T, Khosla S. (2001). Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280:334–339.
   PubMed Web of Science ®Google Scholar
• Jensen JK, Ueland T, Atar D, Gullestad L, Mickley H, Aukrust P, Januzzi JL. (2010). Osteoprotegerin concentrations and prognosis in acute ischaemic stroke. J Intern Med 267:410–417.
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Gerasimidis T, Golemati S, Kapelouzou A, Karayannacos PE, Liapis CD. (2008). The relationship between serum levels of vascular calcification inhibitors and carotid plaque vulnerability. J Vasc Surg 47:55–62.
   PubMed Web of Science ®Google Scholar
• Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. (2004). Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:2175–2180.
   PubMed Web of Science ®Google Scholar
• Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. (2006). The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4:801–811.
   PubMedGoogle Scholar
• Lee BI, Nam HS, Heo JH, Kim DI; Yonsei Stroke Team. (2001). Yonsei Stroke Registry. Analysis of 1,000 patients with acute cerebral infarctions. Cerebrovasc Dis 12:145–151.
   PubMed Web of Science ®Google Scholar
• Nybo M, Johnsen SP, Dethlefsen C, Overvad K, Tjønneland A, Jørgensen JO, Rasmussen LM. (2008). Lack of observed association between high plasma osteoprotegerin concentrations and ischemic stroke risk in a healthy population. Clin Chem 54:1969–1974.
   PubMed Web of Science ®Google Scholar
• Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K. (2008). Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 51:627–633.
   PubMed Web of Science ®Google Scholar
• Reid P, Holen I. (2009). Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 88:1–17.
   PubMed Web of Science ®Google Scholar
• Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR. (2005). Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci 108:237–243.
   PubMed Web of Science ®Google Scholar
• Ridder DA, Schwaninger M. (2009). NF-kappaB signaling in cerebral ischemia. Neuroscience 158:995–1006.
   PubMed Web of Science ®Google Scholar
• Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Scholz H, Andreassen AK, Gullestad L, Damås JK, Frøland SS, Hansson GK, Halvorsen B, Aukrust P. (2006). Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:857–863.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319.
   PubMed Web of Science ®Google Scholar
• Üstündag M, Orak M, Güloglu C, Tamam Y, Sayhan MB, Kale E. (2011). The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality. J Int Med Res 39:780–789.
   PubMed Web of Science ®Google Scholar
• Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njølstad I, Jørgensen L, Hansen JB. (2011). Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study. J Thromb Haemost 9:638–644.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. (2005). Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204:714–723.
   PubMed Web of Science ®Google Scholar